OncoMatch/Clinical Trials/NCT06326736
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Is NCT06326736 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including SJ-Neo006 and Camrelizumab for pancreatic cancer.
Treatment: Camrelizumab · SJ-Neo006 · Gemcitabine+Abraxane — The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Subjects must not have had prior chemotherapy, radiation therapy, or immunotherapy for Pancreatic ductal adenocarcinoma（PDAC）
Cannot have received: radiation therapy
Subjects must not have had prior chemotherapy, radiation therapy, or immunotherapy for Pancreatic ductal adenocarcinoma（PDAC）
Cannot have received: immunotherapy
Subjects must not have had prior chemotherapy, radiation therapy, or immunotherapy for Pancreatic ductal adenocarcinoma（PDAC）
Cannot have received: anti-PD-1 therapy
Prior neoadjuvant treatment, radiation therapy, anti-PD-1 antibody or any other immune therapy for pancreatic ductal adenocarcinoma
Lab requirements
Cardiac function
nyha class iii-iv heart failure, uncontrolled hypertension, clinically significant cardiac dysthythmia, or electrocardiogram abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify